+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, and Region - Forecast to 2028

  • PDF Icon

    Report

  • 273 Pages
  • October 2023
  • Region: Global
  • Markets and Markets
  • ID: 5894900
Description Jump to:

The global antibody drug conjugates market is projected to reach USD 19.8 billion by 2028 from USD 9.7 billion in 2023, at a CAGR of 15.2% during the forecast period. Factors such as the rising prevalence of cancer, robust products under clinical studies, and increased industrial collaborations are likely to drive market growth. For instance, in August 2023, ImmunoGen, Inc. entered into an exclusive collaboration with Takeda Pharmaceutical Company Limited to develop and commercialize ELAHERE in Japan.

The Kadcyla segment held the dominant share in the antibody drug conjugates market

Based on product, the global antibody drug conjugates market is segmented into Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy and others. The Kadcyla segment accounted for the largest share of the market in 2022. Extensive use of Kadcyla for breast cancer treatment is likely to drive the growth of the market. Recent approvals for various disease indications for Polivy and Adcertis are further likely to uplift the market in the coming years.

Breast cancer segment accounted for the largest share of the disease type segment in 2022

Based on disease type, the antibody drug conjugates market is segmented into breast cancer, lung cancer and other diseases. In 2022, the breast cancer segment accounted for the largest share of the antibody drug conjugates market. The segment held the dominant share in the market owing to various factors such as the increasing prevalence of breast cancer coupled with the rising demand for ADCs for breast cancer. The launch of biosimilar is further likely to have a positive impact on the market growth.

Asia-Pacific region is likely to grow at a faster pace

The antibody-drug conjugates market is segmented into North America, Europe, Asia-Pacific, Latin America and Middle East & Africa. Asia-Pacific region is anticipated to grow at a significant CAGR during the forecast period. Rising approvals from the government for ADCs in China and Japan. The launch of the biosimilar Ujvira for the treatment of breast cancer in India is likely to give momentum to the market growth in the region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side - 80% and Demand Side - 20%
  • By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, and Executives - 25%
  • By Region: North America - 40%, Europe - 25%, Asia-Pacific - 20%, Latin America - 10%, and Middle East and Africa - 5%

List of Companies Profiled in the Report

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Daiichi Sankyo Company, Limited (Japan)
  • Seagen Inc. (US)
  • Gilead Sciences, Inc. (US)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Pfizer Inc. (US),
  • Astellas Pharma Inc. (Japan)
  • AstraZeneca (UK)
  • ADC Therapeutics SA (Switzerland)
  • ImmunoGen, Inc. (US)
  • Zydus Group (India)
  • AbbVie Inc. (US)
  • Ambrx (US)
  • LegoChem Biosciences, Inc. (South Korea)
  • Byondis (Netherlands)
  • ProfoundBio (China)
  • RemeGen (China)
  • Sutro Biopharma, Inc. (US)
  • Lepu Biopharma Co. Ltd. (China)
  • Zymeworks Inc. (Canada)
  • Mersana Therapeutics (US)
  • Duality Biologics (China)
  • LaNova Medicines (China)
  • Exelixis, Inc. (US)
  • BiOneCure Therapeutics Inc. (US)
  • Tripartite Therapeutics, Inc. (Taiwan)

Research Coverage

This report provides a detailed picture of the antibody drug conjugates market. It aims to estimate the size and future growth potential of the market across different segments, such as product, route of administration, disease type, application, type and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall antibody drug conjugates market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (Rising incidence of cancer, Increased investment and collaborations by key market players for the development of novel ADCs, Growing number of ADCs in clinical trials, Regulatory support for ADC development), restraints (High manufacturing costs, Side effects associated with ADCs, High attrition rate in product development), opportunities (Adoption of combination therapies, High growth in emerging economies, Emergence of advanced ADCs) and challenges (Technical complexities) are influencing the growth of antibody drug conjugates market.
  • Product Development/Innovation: Detailed insights on newly launched products of the antibody drug conjugates market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the antibody drug conjugates market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the antibody drug conjugates market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players include F. Hoffmann-La Roche Ltd. (Switzerland), Daiichi Sankyo Company, Limited (Japan), Seagen Inc. (US), Gilead Sciences, Inc. (US), Takeda Pharmaceutical Company Limited (Japan), Pfizer Inc. (US), Astellas Pharma Inc (Japan), AstraZeneca (UK), ADC Therapeutics SA (Switzerland), ImmunoGen, Inc. (US), Zydus Group (India) and among others in the antibody drug conjugates market.

Table of Contents

1 Introduction
1.1 Study Objectives
1.2 Market Definition
1.2.1 Inclusions and Exclusions
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered
1.3.3 Currency Considered
1.4 Research Limitations
1.5 Stakeholders
1.6 Recession Impact
2 Research Methodology
2.1 Research Data
Figure 1 Research Design
2.1.1 Secondary Data
2.1.2 Primary Data
Figure 2 Antibody Drug Conjugates Market: Breakdown of Primaries
2.2 Market Size Estimation
Figure 3 Antibody Drug Conjugates Market: Market Size Estimation for Supply-Side Analysis (2022)
Figure 4 Market Size Estimation: Approach 1 (Revenue Share Analysis)
Figure 5 Antibody Drug Conjugates Market: Revenue Share Analysis of F-Hoffman La Roche Ltd.
2.2.1 Primary Insights
Figure 6 Market Validation from Primary Experts
2.2.2 Segment Assessment Methodology
Figure 7 Market Size Estimation Methodology: Top-Down Approach
2.3 Growth Rate Assumptions
Figure 8 Antibody Drug Conjugates Market: CAGR Projection Analysis
Figure 9 Antibody Drug Conjugates Market: Growth Analysis of Drivers, Restraints, Challenges, and Opportunities
2.4 Market Breakdown and Data Triangulation
Figure 10 Data Triangulation Methodology
2.5 Study Assumptions
2.6 Risk Analysis
2.7 Recession Impact Analysis
Table 1 Global Inflation Rate Projection, 2024-2028 (% Growth)
Table 2 US Health Expenditure, 2019-2022 (USD Million)
Table 3 US Health Expenditure, 2023-2027 (USD Million)
3 Executive Summary
Figure 11 Antibody Drug Conjugates Market, by Product, 2023 vs. 2028 (USD Million)
Figure 12 Antibody Drug Conjugates Market, by Disease Type, 2023 vs. 2028 (USD Million)
Figure 13 Antibody Drug Conjugates Market, by Linker Type, 2023 vs. 2028 (USD Million)
Figure 14 Antibody Drug Conjugates Market, by Target Type, 2023 vs. 2028 (USD Million)
Figure 15 Antibody Drug Conjugates Market, by Payload Type, 2023 vs. 2028 (USD Million)
Figure 16 Geographical Snapshot of Antibody Drug Conjugates Market
4 Premium Insights
4.1 Antibody Drug Conjugates Market Overview
Figure 17 Rising Prevalence of Cancer to Drive Market Growth During Forecast Period
4.2 North America: Antibody Drug Conjugates Market, by Disease Type and Country (2022)
Figure 18 Breast Cancer Segment Accounted for Largest Share of North American Antibody Drug Conjugates Market in 2022
4.3 Antibody Drug Conjugates Market Share, by Product, 2023 vs. 2028
Figure 19 Kadcyla Segment to Dominate Market During Forecast Period
4.4 Antibody Drug Conjugates: Geographic Growth Opportunities
Figure 20 Asia-Pacific Countries to Register Higher Growth Rates from 2023 to 2028
5 Market Overview
5.1 Introduction
5.2 Market Dynamics
Figure 21 Antibody Drug Conjugates Market: Drivers, Restraints, Opportunities, and Challenges
Table 4 Antibody Drug Conjugates Market: Impact Analysis of Drivers, Restraints, Opportunities, and Challenges
5.2.1 Drivers
5.2.1.1 Rising Incidence of Cancer
Table 5 Global Increase in Number of Cancer Patients, 2015 vs. 2018 vs. 2035
5.2.1.2 Increasing Investments for ADC Development
5.2.1.3 Growing Number of ADCs in Clinical Trials
Table 6 Asset Ranking for Leading ADC Developers (2019 vs. 2023)
5.2.1.4 Favorable Regulatory Support
5.2.2 Restraints
5.2.2.1 High Manufacturing Costs
5.2.2.2 Side Effects Associated with ADCs
5.2.2.3 High Attrition Rate in Product Development
Table 7 List of Discontinued Antibody Drug Conjugates (2020-2022)
5.2.3 Opportunities
5.2.3.1 Adoption of Combination Therapies
5.2.3.2 High Growth in Emerging Economies
5.2.3.3 Emergence of Advanced ADCs
5.2.4 Challenges
5.2.4.1 Technical Complexities
5.3 Pipeline Analysis
Figure 22 Antibody Drug Conjugates Market: Clinical Trials
5.4 Value Chain Analysis
Figure 23 Antibody Drug Conjugates Market: Value Chain Analysis
5.5 Ecosystem Analysis
5.5.1 Role in Ecosystem
5.6 Technology Analysis
Table 8 Leading Technological Advancements for ADC Generations
5.7 Regulatory Assessment
5.7.1 FDA Regulations on Antibody Drug Conjugates
5.7.1.1 Clinical Pharmacology Considerations
5.7.2 Regulatory Bodies, Government Agencies, and Other Organizations
Table 9 North America: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 10 Europe: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 11 Asia-Pacific: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 12 Latin America: List of Regulatory Bodies, Government Agencies, and Other Organizations
Table 13 Middle East & Africa: List of Regulatory Bodies, Government Agencies, and Other Organizations
5.8 Porter's Five Forces Analysis
Table 14 Antibody Drug Conjugates Market: Porter's Five Forces Analysis
5.8.1 Intensity of Competitive Rivalry
5.8.2 Bargaining Power of Suppliers
5.8.3 Bargaining Power of Buyers
5.8.4 Threat of Substitutes
5.8.5 Threat of New Entrants
5.9 Patent Analysis
5.9.1 List of Major Patents
5.10 Trends/Disruptions Impacting Customers’ Businesses
Figure 24 Growing Use of ADCs for Oncology and Other Chronic Diseases to Drive Market
5.11 Pricing Analysis
Table 15 Antibody Drug Conjugates Market: Pricing Analysis of ADC Products, by Region
Table 16 Antibody Drug Conjugates Market: Pricing Analysis of ADC Products, by Key Players
5.12 Key Conferences and Events
Table 17 Antibody Drug Conjugates Market: Detailed List of Events and Conferences (2023-2024)
5.13 Key Stakeholders and Buying Criteria
Figure 25 Key Stakeholders in Pharmaceutical Companies and Influence on Buying Process
Figure 26 Key Buying Criteria for ADC Products Among End-users
6 Antibody Drug Conjugates Market, by Product
6.1 Introduction
Table 18 Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
6.2 Kadcyla
6.2.1 Launch of Biosimilars to Drive Market
Table 19 Antibody Drug Conjugates Market for Kadcyla, by Region, 2021-2028 (USD Million)
Table 20 North America: Antibody Drug Conjugates Market for Kadcyla, by Country, 2021-2028 (USD Million)
Table 21 Europe: Antibody Drug Conjugates Market for Kadcyla, by Country, 2021-2028 (USD Million)
Table 22 Asia-Pacific: Antibody Drug Conjugates Market for Kadcyla, by Country, 2021-2028 (USD Million)
Table 23 Latin America: Antibody Drug Conjugates Market for Kadcyla, by Country, 2021-2028 (USD Million)
6.3 Enhertu
6.3.1 Rising Incidence of Breast Cancer to Propel Market
Table 24 Antibody Drug Conjugates Market for Enhertu, by Region, 2021-2028 (USD Million)
Table 25 North America: Antibody Drug Conjugates Market for Enhertu, by Country, 2021-2028 (USD Million)
Table 26 Europe: Antibody Drug Conjugates Market for Enhertu, by Country, 2021-2028 (USD Million)
Table 27 Asia-Pacific: Antibody Drug Conjugates Market for Enhertu, by Country, 2021-2028 (USD Million)
Table 28 Latin America: Antibody Drug Conjugates Market for Enhertu, by Country, 2021-2028 (USD Million)
6.4 Adcetris
6.4.1 Growing Cases of Hodgkin Lymphoma to Drive Market
Table 29 Antibody Drug Conjugates Market for Adcetris, by Region, 2021-2028 (USD Million)
Table 30 North America: Antibody Drug Conjugates Market for Adcetris, by Country, 2021-2028 (USD Million)
Table 31 Europe: Antibody Drug Conjugates Market for Adcetris, by Country, 2021-2028 (USD Million)
Table 32 Asia-Pacific: Antibody Drug Conjugates Market for Adcetris, by Country, 2021-2028 (USD Million)
Table 33 Latin America: Antibody Drug Conjugates Market for Adcetris, by Country, 2021-2028 (USD Million)
6.5 Padcev
6.5.1 Rising Incidence of Urothelial Cancer to Drive Market
Table 34 Antibody Drug Conjugates Market for Padcev Market, by Region, 2021-2028 (USD Million)
Table 35 North America: Antibody Drug Conjugates Market for Padcev, by Country, 2021-2028 (USD Million)
Table 36 Europe: Antibody Drug Conjugates Market for Padcev, by Country, 2021-2028 (USD Million)
Table 37 Asia-Pacific: Antibody Drug Conjugates Market for Padcev, by Country, 2021-2028 (USD Million)
Table 38 Latin America: Antibody Drug Conjugates Market for Padcev, by Country, 2021-2028 (USD Million)
6.6 Trodelvy
6.6.1 Increasing Government Approvals for Breast Cancer to Drive Market
Table 39 Antibody Drug Conjugates Market for Trodelvy Market, by Region, 2021-2028 (USD Million)
Table 40 North America: Antibody Drug Conjugates Market for Trodelvy, by Country, 2021-2028 (USD Million)
Table 41 Europe: Antibody Drug Conjugates Market for Trodelvy, by Country, 2021-2028 (USD Million)
Table 42 Asia-Pacific: Antibody Drug Conjugates Market for Trodelvy, by Country, 2021-2028 (USD Million)
Table 43 Latin America: Antibody Drug Conjugates Market for Trodelvy, by Country, 2021-2028 (USD Million)
6.7 Polivy
6.7.1 Rising Prevalence of Non-Hodgkin Lymphoma to Propel Market
Table 44 Antibody Drug Conjugates Market for Polivy Market, by Region, 2021-2028 (USD Million)
Table 45 North America: Antibody Drug Conjugates Market for Polivy, by Country, 2021-2028 (USD Million)
Table 46 Europe: Antibody Drug Conjugates Market for Polivy, by Country, 2021-2028 (USD Million)
Table 47 Asia-Pacific: Antibody Drug Conjugates Market for Polivy, by Country, 2021-2028 (USD Million)
Table 48 Latin America: Antibody Drug Conjugates Market for Polivy, by Country, 2021-2028 (USD Million)
6.8 Other Products
Table 49 Antibody Drug Conjugates Market for Other Products, by Region, 2021-2028 (USD Million)
Table 50 North America: Antibody Drug Conjugates Market for Other Products, by Country, 2021-2028 (USD Million)
Table 51 Europe: Antibody Drug Conjugates Market for Other Products, by Country, 2021-2028 (USD Million)
Table 52 Asia-Pacific: Antibody Drug Conjugates Market for Other Products, by Country, 2021-2028 (USD Million)
Table 53 Latin America: Antibody Drug Conjugates Market for Other Products, by Country, 2021-2028 (USD Million)
7 Antibody Drug Conjugates Market, by Linker Type
7.1 Introduction
Table 54 Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
7.2 Cleavable Linkers
7.2.1 High Compatibility with Broad Range of Drugs to Drive Market
Table 55 Antibody Drug Conjugates Market for Cleavable Linkers, by Region, 2021-2028 (USD Million)
Table 56 North America: Antibody Drug Conjugates Market for Cleavable Linkers, by Country, 2021-2028 (USD Million)
Table 57 Europe: Antibody Drug Conjugates Market for Cleavable Linkers, by Country, 2021-2028 (USD Million)
Table 58 Asia-Pacific: Antibody Drug Conjugates Market for Cleavable Linkers, by Country, 2021-2028 (USD Million)
Table 59 Latin America: Antibody Drug Conjugates Market for Cleavable Linkers, by Country, 2021-2028 (USD Million)
7.3 Non-Cleavable Linkers
7.3.1 Low Toxicity Levels to Support Market Growth
Table 60 Antibody Drug Conjugates Market for Non-Cleavable Linkers, by Region, 2021-2028 (USD Million)
Table 61 North America: Antibody Drug Conjugates Market for Non-Cleavable Linkers, by Country, 2021-2028 (USD Million)
Table 62 Europe: Antibody Drug Conjugates Market for Non-Cleavable Linkers, by Country, 2021-2028 (USD Million)
Table 63 Asia-Pacific: Antibody Drug Conjugates Market for Non-Cleavable Linkers, by Country, 2021-2028 (USD Million)
Table 64 Latin America: Antibody Drug Conjugates Market for Non-Cleavable Linkers, by Country, 2021-2028 (USD Million)
8 Antibody Drug Conjugates Market, by Target Type
8.1 Introduction
Table 65 Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
8.2 HER2
8.2.1 Rising Prevalence of Breast Cancer to Drive Market
Table 66 Antibody Drug Conjugates Market for HER2, by Region, 2021-2028 (USD Million)
Table 67 North America: Antibody Drug Conjugates Market for HER2, by Country, 2021-2028 (USD Million)
Table 68 Europe: Antibody Drug Conjugates Market for HER2, by Country, 2021-2028 (USD Million)
Table 69 Asia-Pacific: Antibody Drug Conjugates Market for HER2, by Country, 2021-2028 (USD Million)
Table 70 Latin America: Antibody Drug Conjugates Market for HER2, by Country, 2021-2028 (USD Million)
8.3 CD22
8.3.1 Increasing Cases of B-Cell Lymphomas to Drive Market
Table 71 Antibody Drug Conjugates Market for CD22, by Region, 2021-2028 (USD Million)
Table 72 North America: Antibody Drug Conjugates Market for CD22, by Country, 2021-2028 (USD Million)
Table 73 Europe: Antibody Drug Conjugates Market for CD22, by Country, 2021-2028 (USD Million)
Table 74 Asia-Pacific: Antibody Drug Conjugates Market for CD22, by Country, 2021-2028 (USD Million)
Table 75 Latin America: Antibody Drug Conjugates Market for CD22, by Country, 2021-2028 (USD Million)
8.4 CD30
8.4.1 Increasing Clinical Trials for Product Launches to Support Market Growth
Table 76 Antibody Drug Conjugates Market for CD30, by Region, 2021-2028 (USD Million)
Table 77 North America: Antibody Drug Conjugates Market for CD30, by Country, 2021-2028 (USD Million)
Table 78 Europe: Antibody Drug Conjugates Market for CD30, by Country, 2021-2028 (USD Million)
Table 79 Asia-Pacific: Antibody Drug Conjugates Market for CD30, by Country, 2021-2028 (USD Million)
Table 80 Latin America: Antibody Drug Conjugates Market for CD30, by Country, 2021-2028 (USD Million)
8.5 Other Target Types
Table 81 Antibody Drug Conjugates Market for Other Target Types, by Region, 2021-2028 (USD Million)
Table 82 North America: Antibody Drug Conjugates Market for Other Target Types, by Country, 2021-2028 (USD Million)
Table 83 Europe: Antibody Drug Conjugates Market for Other Target Types, by Country, 2021-2028 (USD Million)
Table 84 Asia-Pacific: Antibody Drug Conjugates Market for Other Target Types, by Country, 2021-2028 (USD Million)
Table 85 Latin America: Antibody Drug Conjugates Market for Other Target Types, by Country, 2021-2028 (USD Million)
9 Antibody Drug Conjugates Market, by Payload Type
9.1 Introduction
Table 86 Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
9.2 Monomethyl Auristatin E
9.2.1 Cytotoxic Payload for ADC Development to Drive Market
Table 87 Antibody Drug Conjugates Market for Monomethyl Auristatin E, by Region, 2021-2028 (USD Million)
Table 88 North America: Antibody Drug Conjugates Market for Monomethyl Auristatin E, by Country, 2021-2028 (USD Million)
Table 89 Europe: Antibody Drug Conjugates Market for Monomethyl Auristatin E, by Country, 2021-2028 (USD Million)
Table 90 Asia-Pacific: Antibody Drug Conjugates Market for Monomethyl Auristatin E, by Country, 2021-2028 (USD Million)
Table 91 Latin America: Antibody Drug Conjugates Market for Monomethyl Auristatin E, by Country, 2021-2028 (USD Million)
9.3 Calicheamicin
9.3.1 Launch of Calicheamicin-based ADCs to Propel Market
Table 92 Antibody Drug Conjugates Market for Calicheamicin, by Region, 2021-2028 (USD Million)
Table 93 North America: Antibody Drug Conjugates Market for Calicheamicin, by Country, 2021-2028 (USD Million)
Table 94 Europe: Antibody Drug Conjugates Market for Calicheamicin, by Country, 2021-2028 (USD Million)
Table 95 Asia-Pacific: Antibody Drug Conjugates Market for Calicheamicin, by Country, 2021-2028 (USD Million)
Table 96 Latin America: Antibody Drug Conjugates Market for Calicheamicin, by Country, 2021-2028 (USD Million)
9.4 Maytansinoids
9.4.1 Innovative Product Pipeline to Support Market Growth
Table 97 Antibody Drug Conjugates Market for Maytansinoids, by Region, 2021-2028 (USD Million)
Table 98 North America: Antibody Drug Conjugates Market for Maytansinoids, by Country, 2021-2028 (USD Million)
Table 99 Europe: Antibody Drug Conjugates Market for Maytansinoids, by Country, 2021-2028 (USD Million)
Table 100 Asia-Pacific: Antibody Drug Conjugates Market for Maytansinoids, by Country, 2021-2028 (USD Million)
Table 101 Latin America: Antibody Drug Conjugates Market for Maytansinoids, by Country, 2021-2028 (USD Million)
9.5 Other Payload Types
Table 102 Antibody Drug Conjugates Market for Other Payload Types, by Region, 2021-2028 (USD Million)
Table 103 North America: Antibody Drug Conjugates Market for Other Payload Types, by Country, 2021-2028 (USD Million)
Table 104 Europe: Antibody Drug Conjugates Market for Other Payload Types, by Country, 2021-2028 (USD Million)
Table 105 Asia-Pacific: Antibody Drug Conjugates Market for Other Payload Types, by Country, 2021-2028 (USD Million)
Table 106 Latin America: Antibody Drug Conjugates Market for Other Payload Types, by Country, 2021-2028 (USD Million)
10 Antibody Drug Conjugates Market, by Disease Type
10.1 Introduction
Table 107 Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
10.2 Breast Cancer
10.2.1 Rising Cases of Inflammatory Breast Cancer to Drive Market
Table 108 Projection of Breast Cancer Rates
Table 109 Antibody Drug Conjugates Market for Breast Cancer, by Region, 2021-2028 (USD Million)
Table 110 North America: Antibody Drug Conjugates Market for Breast Cancer, by Country, 2021-2028 (USD Million)
Table 111 Europe: Antibody Drug Conjugates Market for Breast Cancer, by Country, 2021-2028 (USD Million)
Table 112 Asia-Pacific: Antibody Drug Conjugates Market for Breast Cancer, by Country, 2021-2028 (USD Million)
Table 113 Latin America: Antibody Drug Conjugates Market for Breast Cancer, by Country, 2021-2028 (USD Million)
10.3 Blood Cancer
10.3.1 Increasing Focus on Clinical Trials for Advanced Conjugates to Propel Market
Table 114 Global Incidence of Blood Cancer
Table 115 Estimated New Blood Cancer Cases in US (2023)
Table 116 Antibody Drug Conjugates Market for Blood Cancer, by Region, 2021-2028 (USD Million)
Table 117 North America: Antibody Drug Conjugates Market for Blood Cancer, by Country, 2021-2028 (USD Million)
Table 118 Europe: Antibody Drug Conjugates Market for Blood Cancer, by Country, 2021-2028 (USD Million)
Table 119 Asia-Pacific: Antibody Drug Conjugates Market for Blood Cancer, by Country, 2021-2028 (USD Million)
Table 120 Latin America: Antibody Drug Conjugates Market for Blood Cancer, by Country, 2021-2028 (USD Million)
10.4 Other Disease Types
Table 121 Antibody Drug Conjugates Market for Other Disease Types, by Region, 2021-2028 (USD Million)
Table 122 North America: Antibody Drug Conjugates Market for Other Disease Types, by Country, 2021-2028 (USD Million)
Table 123 Europe: Antibody Drug Conjugates Market for Other Disease Types, by Country, 2021-2028 (USD Million)
Table 124 Asia-Pacific: Antibody Drug Conjugates Market for Other Disease Types, by Country, 2021-2028 (USD Million)
Table 125 Latin America: Antibody Drug Conjugates Market for Other Disease Types, by Country, 2021-2028 (USD Million)
11 Antibody Drug Conjugates Market, by Region
11.1 Introduction
Table 126 Antibody Drug Conjugates Market, by Region, 2021-2028 (USD Million)
11.2 North America
Figure 27 North America: Antibody Drug Conjugates Market Snapshot
Table 127 North America: Antibody Drug Conjugates Market, by Country, 2021-2028 (USD Million)
Table 128 North America: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 129 North America: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 130 North America: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 131 North America: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 132 North America: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.2.1 US
11.2.1.1 Rising Regulatory Approvals for ADCs to Drive Market
Table 133 US: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 134 US: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 135 US: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 136 US: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 137 US: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.2.2 Canada
11.2.2.1 High R&D Investments for Novel ADCs to Propel Market
Table 138 Canada: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 139 Canada: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 140 Canada: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 141 Canada: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 142 Canada: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.2.3 North America: Recession Impact
11.3 Europe
Table 143 Europe: Antibody Drug Conjugates Market, by Country, 2021-2028 (USD Million)
Table 144 Europe: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 145 Europe: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 146 Europe: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 147 Europe: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 148 Europe: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.3.1 Germany
11.3.1.1 Increasing Collaborations Among Market Players for Cancer Therapeutics to Propel Market
Table 149 Germany: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 150 Germany: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 151 Germany: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 152 Germany: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 153 Germany: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.3.2 France
11.3.2.1 Growing Demand for Personalized Therapeutics to Drive Market
Table 154 France: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 155 France: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 156 France: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 157 France: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 158 France: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.3.3 UK
11.3.3.1 Increasing Cancer Burden to Support Market Growth
Table 159 UK: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 160 UK: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 161 UK: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 162 UK: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 163 UK: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.3.4 Italy
11.3.4.1 Rising Industrial Collaborations for ADC Production to Drive Market
Table 164 Italy: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 165 Italy: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 166 Italy: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 167 Italy: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 168 Italy: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.3.5 Spain
11.3.5.1 Rising Focus on Drug Discovery to Support Market Growth
Table 169 Spain: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 170 Spain: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 171 Spain: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 172 Spain: Antibody Drug Conjugates Market, by Target, 2021-2028 (USD Million)
Table 173 Spain: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.3.6 Rest of Europe
Table 174 Rest of Europe: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 175 Rest of Europe: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 176 Rest of Europe: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 177 Rest of Europe: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 178 Rest of Europe: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.3.7 Europe: Recession Impact
11.4 Asia-Pacific
Figure 28 Asia-Pacific: Antibody Drug Conjugates Market Snapshot
Table 179 Asia-Pacific: Antibody Drug Conjugates Market, by Country, 2021-2028 (USD Million)
Table 180 Asia-Pacific: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 181 Asia-Pacific: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 182 Asia-Pacific: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 183 Asia-Pacific: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 184 Asia-Pacific: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.4.1 China
11.4.1.1 Rising Initiatives for Advanced Therapies to Drive Market
Table 185 China: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 186 China: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 187 China: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 188 China: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 189 China: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.4.2 Japan
11.4.2.1 Favorable Regulatory Support to Propel Market
Table 190 Japan: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 191 Japan: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 192 Japan: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 193 Japan: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 194 Japan: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.4.3 India
11.4.3.1 Emergence of Innovative Biosimilars to Drive Market
Table 195 India: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 196 India: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 197 India: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 198 India: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 199 India: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.4.4 Rest of Asia-Pacific
Table 200 Rest of Asia-Pacific: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 201 Rest of Asia-Pacific: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 202 Rest of Asia-Pacific: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 203 Rest of Asia-Pacific: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 204 Rest of Asia-Pacific: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.4.5 Asia-Pacific: Recession Impact
11.5 Latin America
Table 205 Latin America: Antibody Drug Conjugates Market, by Country, 2021-2028 (USD Million)
Table 206 Latin America: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 207 Latin America: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 208 Latin America: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 209 Latin America: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 210 Latin America: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.5.1 Brazil
11.5.1.1 Regulatory Approvals for Breast Cancer Therapeutics to Drive Market
Table 211 Brazil: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 212 Brazil: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 213 Brazil: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 214 Brazil: Antibody Drug Conjugates Market, by Target, 2021-2028 (USD Million)
Table 215 Brazil: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.5.2 Rest of Latin America
Table 216 Rest of Latin America: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 217 Rest of Latin America: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 218 Rest of Latin America: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 219 Rest of Latin America: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 220 Rest of Latin America: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.5.3 Latin America: Recession Impact
11.6 Middle East & Africa
11.6.1 Rising Product Launches for Cancer Therapeutics to Support Market Growth
Table 221 Middle East & Africa: Antibody Drug Conjugates Market, by Product, 2021-2028 (USD Million)
Table 222 Middle East & Africa: Antibody Drug Conjugates Market, by Linker Type, 2021-2028 (USD Million)
Table 223 Middle East & Africa: Antibody Drug Conjugates Market, by Payload Type, 2021-2028 (USD Million)
Table 224 Middle East & Africa: Antibody Drug Conjugates Market, by Target Type, 2021-2028 (USD Million)
Table 225 Middle East & Africa: Antibody Drug Conjugates Market, by Disease Type, 2021-2028 (USD Million)
11.7 Middle East & Africa: Recession Impact
12 Competitive Landscape
12.1 Introduction
12.2 Strategies Adopted by Key Players
Table 226 Antibody Drug Conjugates Market: Strategies Adopted by Key Players
12.3 Revenue Share Analysis
Figure 29 Revenue Share Analysis of Key Players (2019-2022)
12.4 Market Share Analysis
Figure 30 Market Share Analysis of Key Players (2022)
Table 227 Antibody Drug Conjugates Market: Intensity of Competitive Rivalry
12.5 Company Evaluation Matrix for Key Players
Figure 31 Antibody Drug Conjugates Market: Company Evaluation Matrix (2022)
12.5.1 Stars
12.5.2 Emerging Leaders
12.5.3 Pervasive Players
12.5.4 Participants
12.6 Competitive Benchmarking of 25 Players
12.6.1 Product Footprint of 11 Companies
Table 228 Antibody Drug Conjugates Market: Company Footprint Analysis of Key Players
Table 229 Antibody Drug Conjugates Market: Product Footprint Analysis of Key Players
12.6.2 Regional Footprint of 26 Companies
Table 230 Antibody Drug Conjugates Market: Regional Footprint Analysis of Key Players
12.7 Company Evaluation Matrix for Startups/SMEs
Figure 32 Antibody Drug Conjugates Market: Company Evaluation Matrix for Startups/SMEs (2022)
12.7.1 Progressive Companies
12.7.2 Starting Blocks
12.7.3 Responsive Companies
12.7.4 Dynamic Companies
12.8 Competitive Benchmarking of Startups/SMEs
Table 231 Antibody Drug Conjugates Market: Detailed List of Key Startups/SMEs
Table 232 Antibody Drug Conjugates Market: Competitive Benchmarking of Startups/SMEs
12.9 Competitive Scenario and Trends
12.9.1 Product Launches
Table 233 Antibody Drug Conjugates Market: Product Launches (January 2020-June 2023)
12.9.2 Deals
Table 234 Antibody Drug Conjugates Market: Deals (January 2020-June 2023)

13 Company Profiles
(Business Overview, Products/Solutions/Services Offered, Recent Developments, Analyst's View (Key Strengths/Right to Win, Strategic Choices Made, Weakness/Competitive Threats)*
13.1 Key Players
13.1.1 F. Hoffmann-La Roche Ltd.
Table 235 F. Hoffmann-La Roche Ltd.: Business Overview
Figure 33 F. Hoffmann-La Roche Ltd.: Company Snapshot (2022)
13.1.2 Daiichi Sankyo Company, Limited
Table 236 Daiichi Sankyo Company, Limited: Business Overview
Figure 34 Daiichi Sankyo Company, Limited: Company Snapshot (2022)
13.1.3 Seagen Inc.
Table 237 Seagen Inc.: Business Overview
Figure 35 Seagen Inc.: Company Snapshot (2022)
13.1.4 Gilead Sciences, Inc.
Table 238 Gilead Sciences, Inc.: Business Overview
Figure 36 Gilead Sciences, Inc.: Company Snapshot (2022)
13.1.5 Takeda Pharmaceutical Company Limited
Table 239 Takeda Pharmaceutical Company Limited: Business Overview
Figure 37 Takeda Pharmaceutical Company Limited: Company Snapshot (2022)
13.1.6 Pfizer Inc.
Table 240 Pfizer Inc.: Business Overview
Figure 38 Pfizer Inc.: Company Snapshot (2022)
13.1.7 Astellas Pharma Inc.
Table 241 Astellas Pharma Inc.: Business Overview
Figure 39 Astellas Pharma Inc.: Company Snapshot (2022)
13.1.8 AstraZeneca
Table 242 AstraZeneca: Business Overview
Figure 40 AstraZeneca: Company Snapshot (2022)
13.1.9 ADC Therapeutics SA
Table 243 ADC Therapeutics SA: Business Overview
Figure 41 ADC Therapeutics SA: Company Snapshot (2022)
13.1.10 Immunogen, Inc.
Table 244 Immunogen, Inc.: Business Overview
Figure 42 Immunogen, Inc.: Company Snapshot (2022)
13.1.11 Zydus Group
Table 245 Zydus Group: Business Overview
Figure 43 Zydus Group: Company Snapshot (2022)
13.2 Other Players
13.2.1 AbbVie Inc.
Table 246 AbbVie Inc.: Business Overview
13.2.2 Ambrx
Table 247 Ambrx: Business Overview
13.2.3 LegoChem Biosciences, Inc.
Table 248 LegoChem Biosciences, Inc.: Business Overview
13.2.4 Byondis
Table 249 Byondis: Business Overview
13.2.5 ProfoundBio
Table 250 ProfoundBio: Business Overview
13.2.6 Remegen
Table 251 Remegen: Business Overview
13.2.7 Sutro Biopharma, Inc.
Table 252 Sutro Biopharma, Inc.: Business Overview
13.2.8 Lepu Biopharma Co. Ltd.
Table 253 Lepu Biopharma Co. Ltd.: Business Overview
13.2.9 Zymeworks Inc.
Table 254 Zymeworks Inc.: Business Overview
13.2.10 Mersana Therapeutics
Table 255 Mersana Therapeutics: Business Overview
13.2.11 Duality Biologics
Table 256 Duality Biologics: Business Overview
13.2.12 Lanova Medicines
Table 257 Lanova Medicines: Business Overview
13.2.13 Exelixis, Inc.
Table 258 Exelixis, Inc.: Business Overview
13.2.14 Bionecure Therapeutics Inc.
Table 259 Bionecure Therapeutics Inc.: Business Overview
13.2.15 Tripartite Therapeutics, Inc.
Table 260 Tripartite Therapeutics, Inc.: Business Overview
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, Analyst's View (Key Strengths/Right to Win, Strategic Choices Made, Weakness/Competitive Threats)* Might Not be Captured in Case of Unlisted Companies
14 Appendix
14.1 Discussion Guide
14.2 KnowledgeStore: The Subscription Portal
14.3 Customization Options

Companies Mentioned

  • AbbVie Inc.
  • ADC Therapeutics SA
  • Ambrx
  • Astellas Pharma Inc.
  • AstraZeneca
  • Bionecure Therapeutics Inc.
  • Byondis
  • Daiichi Sankyo Company, Limited
  • Duality Biologics
  • Exelixis, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Immunogen, Inc.
  • Lanova Medicines
  • LegoChem Biosciences, Inc.
  • Lepu Biopharma Co. Ltd.
  • Mersana Therapeutics
  • Pfizer Inc.
  • ProfoundBio
  • Remegen
  • Seagen Inc.
  • Sutro Biopharma, Inc.
  • Takeda Pharmaceutical Company Limited
  • Tripartite Therapeutics, Inc.
  • Zydus Group
  • Zymeworks Inc.

Table Information

Report AttributeDetails
No. of Pages273
PublishedOctober 2023
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 9.7 Billion
Forecasted Market Value ( USD ) by 2028 $ 19.8 Billion
Compound Annual Growth Rate15.2%
Regions CoveredGlobal
No. of Companies Mentioned26

Related Topics

Related Reports

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Antibody Drug Conjugates Market Size, Share & Trends Analysis Report By Application (Blood Cancer, Breast Cancer), By Technology (Type-cleavable, Non-cleavable), By Product, By Target, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 125 Pages
  • Global
From
Antibody Drug Conjugates Global Market Opportunities and Strategies to 2033 - Product Image

Antibody Drug Conjugates Global Market Opportunities and Strategies to 2033

  • Report
  • 303 Pages
  • Global
From
Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugates Contract Manufacturing Market by Linker, Condition, End Use - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030 - Product Image

Antibody Drug Conjugate Market by Mechanism of Action, Drugs, Technology, Indication, End User - Global Forecast 2025-2030

  • Report
  • 181 Pages
  • Global
From
Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Antibody Drug Conjugates Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 184 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.